



A Member of the Roche Group

May 11, 2010

Submission Request to the NCCN Guidelines Panel for Ovarian Cancer

We are aware that the NCCN Guidelines Panel meeting for Ovarian Cancer is scheduled for June 1, 2010. For your consideration, data on the use of Avastin® (Bevacizumab) in the treatment of patients with previously untreated, advanced ovarian cancer will be presented at a plenary session on June 6, 2010 at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago, Illinois. The full results have been embargoed until the ASCO meeting. However, we will be submitting this information for your consideration shortly after the presentation.

The results are from a trial conducted by the Gynecologic Oncology Group, GOG 0218, that is a Phase III, international, multicenter, randomized, placebo-controlled, double-blind study evaluating Avastin with chemotherapy (carboplatin and paclitaxel) followed by maintenance Avastin. The primary endpoint is progression-free survival (PFS) and secondary endpoints include overall survival (OS), PFS by independent review, objective response rate, and safety.

Avastin is not FDA-approved for use in ovarian cancer. Please refer to the enclosed prescribing information for the full FDA-approved indications and safety information.

Submitted by:

Jenny Nugent, PharmD, Scientist  
Medical Communications, Medical Affairs  
Genentech, Inc.  
1 DNA Way, South San Francisco, CA 94080  
(800) 821-8590 | Email [mc-ic-d@gene.com](mailto:mc-ic-d@gene.com)